Abstract
TDF containing HAART is currently the most approved global HIV first-line treatment. Despite its accessibility as a mixture single-tablet regimen for once daily dosing, favorable safety profile and resistance, and effective antiviral activity, it is associated with renal impairment among patients with concurrent use of protease inhibitors and those with advanced HIV virus.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have